Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
| dc.contributor.author | Powles, T. B. | |
| dc.contributor.author | Rodriguez-Vida, A. | |
| dc.contributor.author | Mamtani, R. | |
| dc.contributor.author | Yu, E. Y. | |
| dc.contributor.author | Nam, K. | |
| dc.contributor.author | Imai, K. | |
| dc.contributor.author | Moreno, B. H. | |
| dc.contributor.author | Alva, A. | |
| dc.contributor.author | Csoszi, T. | |
| dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
| dc.contributor.author | Matsubara, N. | |
| dc.contributor.author | Geczi, L. | |
| dc.contributor.author | Cheng, S. Y-S. | |
| dc.contributor.author | Fradet, Y. | |
| dc.contributor.author | Oudard, S. | |
| dc.contributor.author | Vulsteke, C. | |
| dc.contributor.author | Morales Barrera, R. | |
| dc.contributor.author | Flechon, A. | |
| dc.contributor.author | Gunduz, S. | |
| dc.contributor.author | Loriot, Y. | |
| dc.date.accessioned | 2021-03-02T17:07:05Z | |
| dc.date.available | 2021-03-02T17:07:05Z | |
| dc.identifier.citation | Alva A., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y. , Fradet Y., Oudard S., Vulsteke C., Morales Barrera R., et al., "Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_80f1a381-0806-47a4-bd14-64b339fdefa2 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/3573 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2020.08.2252 | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 | |
| dc.type | Bildiri | |
| dc.contributor.department | University of Michigan System , , | |
| dc.identifier.volume | 31 | |
| dc.contributor.firstauthorID | 2286967 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]
